AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Growth promoting treatment normalizes speech frequency in Turner syndrome.
OBJECTIVE To assess objective and subjective voice parameters among Turner syndrome ( TS ) women in relation to genotype , hearing , growth , and previous treatment with growth hormone ( GH ) and and rogen given that lowering of speaking fundamental frequency ( SFF ) during treatment is regarded as a negative side effect . STUDY DESIGN Cross-sectional , controlled for karyotype and age . METHODS Voice function was studied objective ly ( SFF ) and subjectively ( question naire ) in 117 women with TS . RESULTS SFF did not differ between treated and nontreated participants or between patients with a spontaneous versus induced puberty . SFF was dependent on karyotype but not age . Subjective voice change was reported four times more often among treated compared with nontreated TS women ( odds ratio [ OR ] = 4.4 ; 95 % confidence interval [ CI ] : 0.9 - 20.10 ) , whereas voice and articulation problems were reported three times more often among untreated compared with treated cases ( OR = 2.9 ; 95 % CI : 1.0 - 8.3 ) . Voice symptoms were over-represented among patients having micrognathia ( OR = 6.0 ; 95 % CI : 1.6 - 22.3 ) , hearing loss ( OR = 8.6 ; 95 % CI : 1.7 - 43.1 ) , and monosomy ( OR = 6.2 ; 95 % CI : 0.8 - 36.2 ) but not among those with an arched palate . CONCLUSIONS When given to TS girls , GH ( 33 - 66 microg/kg/d ) and and rogen ( 0.05 mg/kg/d ) normalized SFF and reduced voice and articulation problems in adulthood . The TS phenotype includes important voice and speech problems , which in turn are associated with hearing problems , although genotypic , monosomic , and isochromosome patients have more voice problems and also more high-pitched voices than mosaic patients . Most TS women , despite their karyotype or age , exhibit a higher frequency of pitched voice than non-TS women
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .